Showing results (101-110 of 155) with videos related to

Sort By:
Pageof 16
Experimental Hematology & Oncology|March 21, 2023
PD-L1<sup>+</sup> macrophages are associated with favorable features in primary mediastinal (thymic) large B-cell lymphomaRaphael E Steiner, Edwin R Parra, Francisco Vega, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2025
A Phase I Trial of Evorpacept, Lenalidomide and Rituximab for Patients with B-cell Non-Hodgkin LymphomaPaolo Strati, Lei Feng, Andrey Tyshevich, et al.
Blood Advances|August 18, 2023
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohortJackson T Bowers, Jacob Anna, Steven M Bair, et al.
American Journal of Hematology|May 31, 2017
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemiaElias Jabbour, Naval Guastad Daver, Nicholas James Short, et al.
The Oncologist|August 28, 2020
A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium StudyLi Yu, Menghan Shi, Qingqing Cai, et al.
The Journal of Clinical Investigation|July 26, 2022
Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responsesGabrielle Romain, Paolo Strati, Ali Rezvan, et al.
Blood Advances|January 11, 2022
Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapyAjlan Al Zaki, Lei Feng, Grace Watson, et al.
Haematologica|November 11, 2021
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomaRaphael E Steiner, Jose Banchs, Efstratios Koutroumpakis, et al.
JAMA Oncology|July 11, 2024
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled TrialChelsea C Pinnix, Bouthaina S Dabaja, Jillian R Gunther, et al.
Nature Communications|August 7, 2025
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trialPaolo Strati, Lei Feng, Jason R Westin, et al.
Pageof 16